This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The lawsuit alleged that, since October 2013, CVS knowingly filled prescriptions for “dangerous and excessive quantities” of controlled substances that lacked a legitimate medical purpose, were not valid, and were not issued in the “usual course of professional practice. Department of Justice.
According to the statement published by PIB, The National Pharmaceutical Pricing Authority (NPPA) is actively overseeing the pricing of both scheduled and non-scheduled medicines under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). Under DPCO, 2013, formulations are categorised into scheduled and non-scheduled drugs.
This was back in 2013, when such accommodations were a rarity. Even though Erin Booth was not thrilled about having to travel to Philadelphia for a conference at six weeks postpartum, this one at least advertised having a private lactation space.
Bik first became interested in plagiarism as a hobby while working as a researcher at Stanford University in 2013. She later began specializing in image duplication specifically, which she believes is a more serious problem for science as a whole. Read the rest…
billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 Around $25.6 billion had been raised by 556 first-time funds in 2022.
From 2013 to 2022, pharmaceutical and device companies made more than 85 million payments totaling $12.1 The financial ties between drug and device makers and some physicians remains pervasive, despite concerns such relationships may influence medical practice, according to a new analysis of payments made over a recent 10-year span.
The first time I saw Maya (not her real name) huddled under blankets in a hospital bed in 2013, she had been to dozens of inpatient detox programs and residential treatment centers since she had begun using heroin two decades earlier. After every release, she returned to heroin use, usually within days.
The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased cells, and use that data to identify drugs gathering dust on pharmaceutical company shelves that could be repurposed as rare disease treatments.
It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists , published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9.
So far this year, there have been 1,384 VC deals struck in the field, the lowest figure since 2013. New data from Pitchbook and the National Venture Capital Association show that both the number of deals and the amount of money that’s being invested in life science companies are down significantly.
In 2013, it took an average of 9.9 In some cases, failure to show clinical benefit didn’t stop the FDA from converting accelerated approvals into full approvals, and the authors note the agency’s conversion decisions have increasingly been based on less stringent evidence of a drug’s benefits.
AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July.
Founded in 2013, Pear was the most prominent company developing prescription digital therapeutics, or Food and Drug Administration-cleared software applications ordered by doctors to treat health conditions. Click Therapeutics, Welt Corp, Harvest Bio, and Nox Health Group each acquired bits of the company for $6.05
Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame with the same goal of turning the nascent CRISPR gene-editing technology into medicines.
Over the past decade, the number of research misconduct allegations reported to the National Institutes of Health has more than doubled, climbing from 74 in 2013 to 169 in 2022. And it’s hardly alone. And scientific sleuths are finding plenty of other problems that don’t always qualify as outright misconduct.
This brings the total number of people who have accessed the service since it launched in 2013 to almost 1.25m. The pharmacy common ailments service in Wales saw 420,951 patients in the last 12 months, new figures from the Welsh Government have revealed.
The company, which last month pleaded guilty to a misdemeanor, admitted that, from April 2012 through May 2013, some of its sales representatives marketed its medicine, also known as oxymorphone, to doctors by touting the drug as abuse deterrent, as well as resistant to tampering and crushing.
He has been part of the C-suite at Sage Therapeutics since 2013. Longtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech incubator with global investment giant CBC Group. Sage announced this week that Jonas would leave the company to join a private equity firm. billion deal with Biogen.
For example, the share of Mexican Americans taking insulin who achieved good blood-sugar control sharply dropped to 10% during the period of 2013 to 2020 from 25% during 1988 to 1994, researchers reported Tuesday in JAMA Network Open. Read the rest…
In 2013, I sat down at my computer and secured the URL t1international.com. I wanted a place where I could collect and share everything I was learning about the global insulin price crisis. I was only 25 years old, and I had already been living with type 1 diabetes for more than two decades.
million from 2013 to 2019, presumably due to the company payments, according to the study, which was published in JAMA Health Forum. Physicians who did not accept payments prescribed Avastin 46% of the time, nearly twice as often as those who accepted payments. As a result, Medicare shelled out an estimated $642.8
Case in point: Under the seemingly benign title, “Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval,” an article published recently in the Journal of the American Medical Association claims that among “cancer drugs granted accelerated approval from 2013 to 2017, 41% (19/46) did not improve (..)
San Francisco-based Carbon said that Elevance — formerly known as Anthem, which operates the Anthem Blue Cross plan in California — had refused to increase its payment rate in the state beyond 2013 levels, which was “no longer tenable as a livable wage.” ” Continue to STAT+ to read the full story…
A federal law that went into effect in 2013 requires the FDA to identify ingredients needed to satisfy an unmet “clinical need” and to include those on a list for use by large compounding pharmacies.
When it hit the market in 2013, the drug revolutionized the treatment of these cancers and represented a major step forward from chemotherapy and some other drugs at the time. NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia has been a drug called ibrutinib, made by AbbVie.
In the spring of 2013, I had just visited a lab focused on gene and cell therapies at Baylor College of Medicine. Bluebird Bio , which would soon launch a successful IPO , had licensed its technology from the same lab and was about to announce a major collaboration with Celgene and Baylor.
The two men worked together from 2013 until 2022, when Jonas left to start a biotech incubator with funding from investment giant CBC Group. The VC firm has hired Jeff Jonas, Sage’s former chief executive, and Al Robichaud, Sage’s former chief scientific officer, as partners, the team told STAT exclusively.
are charged with knowingly selling defective lead testing machines between 2013 and 2017 that generated inaccurate results for tens of thousands of children across the country and for clients of at least one international relief organization, federal prosecutors said. Three former executives at Magellan Diagnostics Inc.
Central Texas’ Scott and White was absorbed into Baylor in 2013. Wisconsin’s Marshfield Clinic agreed to merge with Duluth-based Essentia Health in October 2022 after a lengthy string of operating losses, though the merger fell apart recently.
Hospitals ran short of essential treatment medications and were unable to source those drugs from manufacturers or from the outsourcing facilities that had been authorized by Congress in 2013 to “fill the gap” in such situations.
based company was founded in 2013 and has raised $60 million to date. Perekupka said Freespira hopes to enroll 2,500 people in its treatment this year — twice last year’s sales — and to double its patients again in 2025 and 2026. The Kirkland, Wash.-based
Indeed, on July 1, drugmakers raised the wholesale price on over 123 drugs in what’s the largest number of mid-year price hikes since 2013, according to data from drug pricing nonprofit 46brooklyn and the Elsevier Gold Standard Drug Database. Continue to STAT+ to read the full story…
In his 2013 State of the Union address, he laid out a bold vision to fund and accelerate brain research: “If we want to make the best products, we also have to invest in the best ideas.
In 2013, Kevan Shokat, a biologist at the University of California, San Francisco, discovered a key chemical vulnerability in a specific subset of mutant oncogenic KRAS that made it possible to design small molecules that would bind to the protein. ” In the last few years, that attitude has sharply turned around.
In late 2013, the FDA had conditionally approved the biopsies as a part of an early feasibility study, which it limited to six patients at the medical center who were getting DBS for treatment-resistant depression.
A 2013 trial of the first iteration of Cologuard, known as DeeP-C, showed the test is 92% sensitive and 87% specific. The new Cologuard test correctly detected cancer 94% of the time, and it correctly returned a negative result 91% of the time, test characteristics known as sensitivity and specificity, respectively.
From 2013 to 2022, pharmaceutical and device companies made more than 85 million payments totaling $12.1 Financial ties between drug and device makers and some physicians remain pervasive, despite concerns such relationships may influence medical practice , STAT writes, citing a new analysis of payments made over a recent 10-year span.
Pillai (2013), poet-translator Madan Lal Madhu (2001), former Prime Minister Inder Kumar Gujral, Justice V.R. Dr Saxena joins an eminent group of Indians who have received the Order of Friendship , including chess grandmaster Viswanathan Anand (2018), former Member of Parliament Murli Manohar Joshi, scientist Dr A.S.
Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years
A report from the Food Foundation found the height of five-year olds has been falling since 2013, with UK children now shorter than those in nearly […] The post UK children shorter, more obese and less healthy than 20 years ago appeared first on The Pharmacist.
This period included the implementation of novel designation types: qualified infectious disease product designation (in 2012), breakthrough therapy (2013), rare pediatric drug designation (2014), and regenerative medicine advanced therapy designation (2017). Over this period, annual designations awarded by the FDA increased almost four-fold.
2013 Dec;15(4):90-2. Epub 2013 Nov 7. Sivalingam SK, Gadiraju VT, Hariharan MV, Atreya AR, Flack JE, Aziz H. Flecainide toxicity–treatment with intravenous fat emulsion and extra corporeal life support. Acute Card Care. doi: 10.3109/17482941.2013.841949. PMID: 24200150. Bruccoleri RE, Burns MM. J Med Toxicol.
It’s hard to believe that I have been following pharmacist board certifications and helping pharmacists pass the BCPS exam for over 10 years since I first passed it in 2013! Each year in updating and creating our study materials, I review the content outline and any possible changes in the BCPS exam.
111
111
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content